Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–1 of 1 stories
A case report highlights the clinical efficacy and potential cardiac toxicity of first-line treatment with dabrafenib and trametinib in patients with advanced BRAF V600_K601delinsE-mutated lung adenocarcinoma. This review adds to the understanding of treatment outcomes and safety profiles in this specific mutation.
Read full storyGet the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.